Your session is about to expire
← Back to Search
Itacitinib for Blood Cancer
Study Summary
This trial tests whether a new drug could help prevent complications in "mini" transplants for blood cancer patients. It may also reduce the need for other drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 439 Patients • NCT03139604Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have HIV.I have not had a bone marrow transplant from another person.I do not have any infections that aren't responding to treatment.I do not have an active hepatitis B or C infection needing treatment.I had a stem cell transplant using my own cells more than 3 months ago.My cancer has not spread to my brain or spinal cord.I have a family member who can donate stem cells to me.You are eligible if you have certain types of leukemia, myelodysplastic syndrome, myeloproliferative disease, or multiple myeloma and meet specific age and organ function requirements.
- Group 1: Itacitinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being evaluated in this research?
"Affirmative. Clinicaltrials.gov has information that indicates this clinical trial is recruiting participants with vigor, after first being posted on July 6th 2023 and most recently updated the same day. 32 volunteers are needed from one medical center."
Are there any available vacancies left for potential participants in this medical research?
"Affirmative. According to clinicaltrials.gov, this study is actively enrolling participants with the original posting date being July 6th 2023 and a recent update on that same day. 32 individuals are needed from one medical centre for enrolment in this trial."
To what extent do the risks of Itacitinib outweigh its potential benefits?
"Our team has assigned Itacitinib a safety rating of 1 due to the fact that this is an early-phase trial and there is just scant evidence supporting its efficacy and security."
Share this study with friends
Copy Link
Messenger